| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01120275 Details | 2016-06-14 Interventional | 2 | 36 | 2,2-dimethyl-N-… Hutchinson's Me… Lentigo Melanoma Acral Lentigino… Lentigo Maligna… Nodular Maligna… Recurrent Melan… Solar Radiation… Stage IV Melano… Superficial Spr… | Administratively complete. - | |||
| NCT01658527 2012-002122-67 Details | 2016-06-10 Interventional | 2 | 0 | Bicalutamide Prostatic Neopl… Prostate Cancer | Pharmaceutical company has terminated orteronel (TAK-700) development for Prostate Cancer - | |||
| NCT02791256 2005-000198-22 Details | 2016-06-08 Interventional | 3 | 23 | Peginterferon a… Ribavirin Hepatitis Hepatitis A Hepatitis C Hepatitis C, Ch… | - - | |||
| NCT00478972 Details | 2016-06-08 Interventional | 3 | 321 | Rimonabant Diabetes Mellit… Diabetes Mellit… Obesity | Company decision taken in light of demands by certain national health authorities - | |||
| NCT00574275 2007-003476-19 Details | 2016-06-07 Interventional | 3 | [1 Refs] | 546 | Aflibercept Gemcitabine Pancreatic Neop… Pancreatic Neop… | Data Monitoring Committee concluded after a planned interim analysis that aflibercept added to
gemcitabine would be unable to demonstrate improved survival As the study was terminated due to futility, some changes were made to the planned analyses, and the analyses for the following outcome measures were not performed: Objective Response Rate (ORR) Clinical Benefit | ||
| NCT02060955 Details | 2016-06-06 Interventional | 2 | 25 | Bevacizumab Irinotecan Glioblastoma Glioblastoma Mu… | Substantial design modifications required. - | |||
| NCT00478595 Details | 2016-06-06 Interventional | 3 | 458 | Hypoglycemic Ag… Rimonabant Diabetes Mellit… Diabetes Mellit… Obesity | Company decision taken in light of demands by certain national health authorities - | |||
| NCT01003678 Details | 2016-06-03 Interventional | 1 | 4 | Clofarabine Myelodysplastic… Preleukemia Syndrome Myelodysplastic… | Drug provider withdrew support - | |||
| NCT00313053 Details | 2016-06-03 Interventional | 1 | 4 | Vincristine Leukemia Leukemia, Lymph… Precursor Cell … Acute Lymphoid … Leukemia, Lymph… | - - | |||
| NCT01549964 2011-001752-10 Details | 2016-06-02 Interventional | 3 | 916 | Sitagliptin Pho… Glycemic Contro… | Due to concerns about potential liver safety (See Detailed Description) - | |||
| NCT02786732 Details | 2016-06-01 Interventional | 3 | 15 | Antibodies, Mon… Brodalumab Ustekinumab Psoriasis | Sponsor - | |||
| NCT02349516 Details | 2016-06-01 Interventional | 2 | 0 | Ophthalmic Solu… Squalamine Diabetic Retino… Macular Edema | Study cancelled as of 9/12/15. 0 subjects enrolled. - | |||
| NCT01829477 2013-000007-17 Details | 2016-06-01 Interventional | 3 | 33 | Glimepiride Diabetes Mellit… Diabetes Mellit… | Due to potential concerns about liver safety (See Detailed Description) - | |||
| NCT01743885 Details | 2016-06-01 Interventional | 3 | 55 | Acebutolol Propranolol Hemangioma Hemangioma, Cap… Port-Wine Stain | - - | |||
| NCT01481116 2011-001731-24 Details | 2016-06-01 Interventional | 3 | 2454 | Glimepiride Diabetes Mellit… Diabetes Mellit… | Due to potential concerns about liver safety (See Detailed Description) - | |||
| NCT01407679 Details | 2016-06-01 Interventional | 2 | 7 | Alitretinoin Lupus Erythemat… Lupus Erythemat… | - - | |||
| NCT02031965 Details | 2016-05-30 Interventional | 1 | 2 | Dexamethasone Astrocytoma Glioblastoma Gliosarcoma Neoplasms, Neur… Oligodendroglio… Recurrence Recurrent Child… Recurrent Child… Recurrent Child… Recurrent Child… Recurrent Child… Recurrent Child… Recurrent Child… | - - | |||
| NCT02052635 Details | 2016-05-27 Interventional | 4 | 34 | Clopidogrel Ticagrelor Acute Coronary … Syndrome Non-ST Elevatio… | Patient recruitment challenges, low enrolment, and a forecasted inability to complete the study
in an acceptable timeframe The target sample size for this study was 100 patients. But due to recruitment challenges and low enrolment,the study was terminated early with only 13 pateints randomized. No formal statistical analyses were performed. | |||
| NCT01721330 Details | 2016-05-27 Interventional | 4 | 3 | Naltrexone Attention Defic… Hyperkinesis ADHD Attention Defic… | Competing studies The study was terminated prior to completion due to competing studies. Therefore, only one subject in each group was analyzed. | |||
| NCT00585442 Details | 2016-05-27 Interventional | 1 | 12 | Calcitriol Vitamin D Vitamin D Defic… Hypertension | Lack of quality data - |